Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-acetyltransferase 16 is a protein-coding gene product classified as a probable acetyltransferase. In humans, NAT16 shows only trace enzyme activity for N-acetylation of L-histidine, and its physiological substrate remains unknown[2][6]. In ectothermic vertebrates such as ray-finned fishes, amphibians, and reptiles, the homologous enzyme (HISAT) encoded by the NAT16 ortholog is responsible for the brain- and lens-specific synthesis of Nα-acetylhistidine, suggesting a specialized evolutionary role[1]. In humans, expression data and functional annotation indicate limited activity and uncertain biological significance, with no reported involvement in major disease processes, therapeutic targeting, or drug interactions to date[2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable N-acetyltransferase 16 (NAT16).